AR039659A1 - Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa - Google Patents
Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasaInfo
- Publication number
- AR039659A1 AR039659A1 ARP030101420A ARP030101420A AR039659A1 AR 039659 A1 AR039659 A1 AR 039659A1 AR P030101420 A ARP030101420 A AR P030101420A AR P030101420 A ARP030101420 A AR P030101420A AR 039659 A1 AR039659 A1 AR 039659A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- group
- heteroaryl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona N-sustituida de fórmula (1) en la que el anillo X es un anillo heterocíclico de 5-7 miembros, y donde A, Y, B y G son como se definen en la memoria descriptiva; y a composiciones farmacéuticas y procedimientos de tratamiento de la inflamación, cánceres y otros trastornos. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque dicho anillo X es un anillo heterocíclico de 5-7 miembros seleccionado entre el grupo compuesto por el grupo de fórmulas (2) donde cada línea de trazos representa un doble enlace opcional; donde cada uno de R1, R2, R3, R4 R5, R6, R7, R8, R9, R10, R11, R12 y R13 se selecciona independientemente entre el grupo compuesto por H, alquilo C1-4, alquenilo C1-4, alquinilo C1-4, arilo C6-10, heteroarilo C1-10, cicloalquilo C1-8 y heterociclilo C1-10; donde cada uno de dichos R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 y R13 alquilo C1-4, arilo C6-10, heteroarilo C1-10, cicloalquilo C3-8 y heterociclilo C1-10 puede estar opcionalmente sustituido sobre cualquiera de los átomos de C del anillo capaces de soportar un sustituyente adicional con 1 a 3 sustituyentes por anillo seleccionados independientemente entre halo, alquilo C1-4, alcoxi C1-4, -CN, -OH y -NH2; donde cada uno de dichos R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, y R13 heteroarilo C1-10 y heterociclilo C1-10 puede estar opcionalmente sustituido sobre cualquier átomo de N del anillo capaz de soportar un sustituyente adicional seleccionado independientemente entre el grupo compuesto por alquilo C1-4 y alquil C1-4-(C=O)-; A es arilo C6-10 o heteroarilo C2-10; donde dicho arilo o heteroarilo C2-10 puede estar opcionalmente sustituido sobre cualquiera de los átomos de C del anillo capaz de soportar un sustituyente adicional con 1 o 2 sustituyentes por anillo seleccionados independientemente entre F, Cl, Br, CN, OH, alquilo C1-4, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, alcoxi C1-4 y cicloalquiloxi C3-8. Y se selecciona entre el grupo compuesto por un enlace -O-, -S-, >C=O, >SO2, >S=O, -CH2O-, -OCH2-, -CH2S-, -SCH2-, -CH2SO-, -CH2SO2-, -SOCH2-, -SO2CH2-, >NR14; -[N(R14)]CH2-, -CH2[N(R14)]-, -CH2-, -CH=CH-, -CsC-, -[N(R14)]-SO2- y -SO2[N(R14)]-, R14 se selecciona entre el grupo compuesto por H y alquilo C1-4; B es un heterociclilo que contiene al menos un átomo de N; donde un átomo de N de B está unido a un átomo de C de G; con la condición de que el grupo -B-G- no sea metilazetidinilo o metilpiperidinilo donde dicho B puede estar opcionalmente sustituido sobre cualquiera de los átomos de C del anillo capaces de soportar un sustituyente adicional con 1 o 2 sustituyentes por anillo seleccionados independientemente entre F, Cl, Br, CN, OH, alquilo C1-4, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, alcoxi C1-4, cicloalquil C3-8-oxi, arilo C6-10, cicloalquilo C3-8; heteroarilo C1-10 y heterociclilo C1-10; G es alquilo C1-6 o R15-(CR16R17)p-; p es un número entero de 0 a 4; donde dicho G alquilo C1-6 puede estar opcionalmente sustituido sobre cualquiera de los átomos de C capaces de soportar un sustituyente adicional con uno a tres sustituyentes por alquilo C1-6 seleccionados independientemente entre F, Cl, Br, CN, OH, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, alcoxi C1-4, NH2, alquil(C1-4)-NH-, [alquil(C1-4)]2-N- y cicloalquil C3-8-oxi; R15 se selecciona entre el grupo compuesto por cicloalquilo C3-8, arilo C6-10, heteroarilo C1-10 y heterociclilo C1-10; donde cada uno de dichos R15 arilo C6-10, cicloalquilo C3-8, heteroarilo C1-10 y heterociclilo C1-10 puede estar opcionalmente sustituido sobre cualquier átomo de C del anillo capaz de soportar un sustituyente adicional con 1 a 3 sustituyentes por anillo seleccionados independientemente entre F, Cl, Br, CN, OH, alquilo C1-4, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, alcoxi C1-4, alcoxi(C1-4)-alquilo(C1-4), -NH2, alquil(C1-4)-NH, [alquil(C1-4)]2-N- y cicloalquil (C3-8)-oxi; donde cada uno de dichos R15 cicloalquilo C3-8 y heterociclilo C1-10 también puede estar opcionalmente sustituido por oxo; donde cada uno de dichos R15 heteroarilo C1-10 y heterociclilo C1-10 puede estar opcionalmente sustituido sobre cualquier átomo de N del anillo capaz de soportar un sustituyente adicional seleccionado independientemente entre el grupo compuesto por alquilo C1-4 y alquil C1-4-(C=O)-,cada uno de R16 y R17 se selecciona independientemente entre el grupo compuesto por H y alquilo C1-4; o R16 y R17 opcionalmente pueden tomarse junto con el C al que están unidos para formar un anillo carbocíclico de 3 a 8 miembros, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37615902P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039659A1 true AR039659A1 (es) | 2005-03-02 |
Family
ID=29270771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101420A AR039659A1 (es) | 2002-04-26 | 2003-04-24 | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6900201B2 (es) |
| EP (1) | EP1501833B1 (es) |
| JP (1) | JP2005529895A (es) |
| AR (1) | AR039659A1 (es) |
| AT (1) | ATE308544T1 (es) |
| AU (1) | AU2003216660A1 (es) |
| BR (1) | BR0308787A (es) |
| CA (1) | CA2480092A1 (es) |
| DE (1) | DE60302150D1 (es) |
| GT (1) | GT200300093A (es) |
| MX (1) | MXPA04010545A (es) |
| PA (1) | PA8572701A1 (es) |
| PE (1) | PE20040450A1 (es) |
| TW (1) | TW200400193A (es) |
| UY (1) | UY27777A1 (es) |
| WO (1) | WO2003091258A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003090751A1 (en) * | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors |
| DE60301574T2 (de) | 2002-04-26 | 2006-01-12 | Pfizer Products Inc., Groton | Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren |
| WO2003091258A1 (en) | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| ES2333008T3 (es) | 2002-12-20 | 2010-02-16 | Glaxo Group Limited | Derivados de benzo(d)azepina para el tratamiento de trastornos neurologicos. |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| WO2006125645A2 (en) * | 2005-05-24 | 2006-11-30 | U3 Pharma Ag | Inhibitors of mmp-15 in cancer treatment |
| EP2537849A3 (en) | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| NZ577798A (en) * | 2006-12-21 | 2012-04-27 | Vertex Pharma | 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| JP5486928B2 (ja) * | 2007-02-26 | 2014-05-07 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックウレアおよびカルバメートインヒビター |
| JP5470557B2 (ja) * | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| JP5490014B2 (ja) | 2007-12-11 | 2014-05-14 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の環状尿素阻害剤 |
| TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| US8592409B2 (en) * | 2008-01-24 | 2013-11-26 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| EP2252598A2 (en) * | 2008-02-11 | 2010-11-24 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2715290A1 (en) * | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP2011513483A (ja) * | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| WO2009117109A1 (en) * | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| CA2723034A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2009134392A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8242111B2 (en) * | 2008-05-01 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| US8138178B2 (en) * | 2008-05-01 | 2012-03-20 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| KR20110050459A (ko) | 2008-07-25 | 2011-05-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| TW201016691A (en) | 2008-07-25 | 2010-05-01 | Boehringer Ingelheim Int | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP5679997B2 (ja) | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
| US8680093B2 (en) | 2009-04-30 | 2014-03-25 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US20100331320A1 (en) * | 2009-04-30 | 2010-12-30 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2440537A1 (en) | 2009-06-11 | 2012-04-18 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| SG10201405826RA (en) | 2009-06-17 | 2014-12-30 | Vertex Pharma | Inhibitors of influenza viruses replication |
| US8883778B2 (en) | 2009-07-01 | 2014-11-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン |
| EA201300522A1 (ru) | 2010-11-02 | 2013-11-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Фармацевтические комбинации для лечения метаболических нарушений |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| PT3068776T (pt) | 2013-11-13 | 2019-08-26 | Vertex Pharma | Inibidores da replicação de vírus da gripe |
| WO2015073481A1 (en) | 2013-11-13 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| SI3348547T1 (sl) | 2015-09-11 | 2020-10-30 | Sumitomo Dainippon Pharma Co., Ltd. | Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple skleroze |
| WO2020113088A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
| CN117003754B (zh) * | 2022-04-28 | 2025-07-25 | 腾讯科技（深圳）有限公司 | 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| CN1295227C (zh) | 1997-06-21 | 2007-01-17 | 罗赫诊断器材股份有限公司 | 具有抗转移和抗肿瘤活性的巴比土酸衍生物 |
| US6265578B1 (en) | 1999-02-12 | 2001-07-24 | Hoffmann-La Roche Inc. | Pyrimidine-2,4,6-triones |
| PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
| WO2002034753A2 (en) * | 2000-10-26 | 2002-05-02 | Pfizer Products Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| WO2002034726A2 (en) | 2000-10-26 | 2002-05-02 | Pfizer Products Inc. | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| DE60301574T2 (de) | 2002-04-26 | 2006-01-12 | Pfizer Products Inc., Groton | Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren |
| WO2003091258A1 (en) | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
-
2003
- 2003-04-15 WO PCT/IB2003/001508 patent/WO2003091258A1/en not_active Ceased
- 2003-04-15 AU AU2003216660A patent/AU2003216660A1/en not_active Abandoned
- 2003-04-15 MX MXPA04010545A patent/MXPA04010545A/es not_active Application Discontinuation
- 2003-04-15 BR BR0308787-5A patent/BR0308787A/pt not_active Application Discontinuation
- 2003-04-15 EP EP03712571A patent/EP1501833B1/en not_active Expired - Lifetime
- 2003-04-15 DE DE60302150T patent/DE60302150D1/de not_active Expired - Lifetime
- 2003-04-15 AT AT03712571T patent/ATE308544T1/de not_active IP Right Cessation
- 2003-04-15 JP JP2003587816A patent/JP2005529895A/ja active Pending
- 2003-04-15 CA CA002480092A patent/CA2480092A1/en not_active Abandoned
- 2003-04-22 PE PE2003000397A patent/PE20040450A1/es not_active Application Discontinuation
- 2003-04-24 AR ARP030101420A patent/AR039659A1/es unknown
- 2003-04-24 UY UY27777A patent/UY27777A1/es not_active Application Discontinuation
- 2003-04-24 GT GT200300093A patent/GT200300093A/es unknown
- 2003-04-24 TW TW092109609A patent/TW200400193A/zh unknown
- 2003-04-25 US US10/423,779 patent/US6900201B2/en not_active Expired - Fee Related
- 2003-04-25 PA PA20038572701A patent/PA8572701A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1501833A1 (en) | 2005-02-02 |
| WO2003091258A1 (en) | 2003-11-06 |
| TW200400193A (en) | 2004-01-01 |
| GT200300093A (es) | 2004-05-18 |
| UY27777A1 (es) | 2003-11-28 |
| JP2005529895A (ja) | 2005-10-06 |
| PA8572701A1 (es) | 2003-12-10 |
| US6900201B2 (en) | 2005-05-31 |
| BR0308787A (pt) | 2005-01-11 |
| US20040010141A1 (en) | 2004-01-15 |
| DE60302150D1 (en) | 2005-12-08 |
| ATE308544T1 (de) | 2005-11-15 |
| MXPA04010545A (es) | 2005-01-25 |
| CA2480092A1 (en) | 2003-11-06 |
| PE20040450A1 (es) | 2004-07-21 |
| AU2003216660A1 (en) | 2003-11-10 |
| EP1501833B1 (en) | 2005-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR046767A1 (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| AR050619A1 (es) | Derivados de adamantilo | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR035069A1 (es) | Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento | |
| AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
| AR010378A1 (es) | Novedosos compuestos con efecto analgesico, uso de los mismos para la preparacion de un medicamento y como agente de diagnostico, composicion farmaceutica, proceso para la preparacion de dichos compuestos y compuestos intermediarios | |
| ECSP941102A (es) | Pirazolopirimidinonas para el tratamiento de la impotencia | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR059726A1 (es) | Moduladores de 11 beta hidroxil esteroide deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos, y metodos de uso de los mismos | |
| AR068466A1 (es) | Cianoisoquinolina | |
| AR039933A1 (es) | Indoles sustituidos para tratamiento de desordenes respiratorios | |
| AR035991A1 (es) | Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio | |
| AR037736A1 (es) | Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r) | |
| AR035695A1 (es) | Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos | |
| AR035362A1 (es) | Compuestos inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona, composiciones farmaceuticas, y metodos de tratamiento con dichos compuestos | |
| AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR039660A1 (es) | Inhibidores de aril-heteroariloxi-ariloxi-pirimidin-2,4,6-triona metaloproteinasa | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |